AndroGel Delayed-Onset Side Effects: What Takes Weeks or Months to Appear

Why Delayed-Onset Side Effects Are the Bigger Clinical Risk

Immediate reactions to AndroGel, such as local redness or mild skin dryness, are easy to notice and easy to address. The delayed effects are different. They accumulate below the threshold of symptoms for weeks or months, and by the time a patient notices something, the physiological change may already be clinically significant.

The FDA prescribing information for AndroGel 1.62% lists erythrocytosis, thromboembolic events, and prostate abnormalities as effects that require monitoring over time, not just at initiation. [1] That framing reflects the reality that transdermal testosterone raises serum levels gradually, and organ-level responses, particularly in bone marrow, the prostate, and the testes, lag behind serum changes by weeks or months.

Understanding this timeline helps clinicians schedule labs correctly and helps patients know what to watch for after the first few months of therapy.

Erythrocytosis: The Most Common Delayed Lab Finding

What It Is and When It Appears

Erythrocytosis, a rise in red blood cell mass reflected by hematocrit above 54% in men, is the most frequently reported delayed lab abnormality in testosterone therapy. Testosterone stimulates erythropoietin secretion from the kidney and also acts directly on bone marrow progenitor cells. [2] The effect on hematocrit is not immediate. In clinical studies of transdermal testosterone, hematocrit changes typically become measurable between weeks 4 and 12, and peak effect may not arrive until 6 months into therapy.

A 2019 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (JCEM) pooled data from 35 randomized controlled trials and found that testosterone therapy increased hematocrit by a weighted mean of 3.18 percentage points (95% CI 2.37 to 3.99) compared with placebo. [3] That shift is enough to push men who start near the upper limit of normal into polycythemia range.

Why Transdermal Route Still Carries Risk

Transdermal delivery is often said to produce less erythrocytosis than intramuscular injections because it avoids the large peak-trough swings of injectable esters. That is partially true for gel compared with depot formulations, but the absolute risk is not trivial. The TRAVERSE trial, a cardiovascular safety study of testosterone replacement therapy in men with hypogonadism and elevated cardiovascular risk, reported that hematocrit exceeded 54% in 5.1% of testosterone-treated participants versus 1.5% of placebo participants. [4]

Clinical Thresholds and Management

The Endocrine Society 2018 clinical practice guideline recommends checking hematocrit at baseline, at 3 months, and then annually. If hematocrit exceeds 54%, the guideline advises stopping therapy, investigating for secondary causes of polycythemia, and restarting at a lower dose once hematocrit normalizes. [5] The elevated hematocrit matters clinically because erythrocytosis raises whole-blood viscosity, which may increase the risk of venous thromboembolism.

Prostate-Specific Antigen Rise and Prostate Effects

The Timeline of PSA Changes

PSA does not rise on day one of testosterone therapy. In most clinical trials, statistically significant PSA increases appear between 3 and 6 months after initiating treatment. The T-Trial (N=788), a coordinated set of seven placebo-controlled trials in men aged 65 and older with low testosterone, found that PSA increased by a mean of 0.25 ng/mL in the testosterone group versus 0.07 ng/mL in the placebo group at 12 months. [6] That difference, while modest, underscores why a 3-month PSA check is clinically necessary.

Who Is at Greatest Risk

Men with pre-existing benign prostatic hyperplasia (BPH) may notice worsening urinary symptoms, including hesitancy, frequency, or reduced stream, starting around weeks 6 to 12. Testosterone does not cause prostate cancer, but it can stimulate growth of pre-existing androgen-sensitive tissue. The FDA label for AndroGel carries a warning that patients with BPH treated with androgens may be at increased risk for worsening urinary obstruction. [1]

Monitoring Protocol

The Endocrine Society guideline specifies a PSA check at 3 to 6 months after starting testosterone, then following standard age-based prostate cancer screening guidelines thereafter. [5] A PSA rise of more than 1.4 ng/mL above baseline within the first year, or any PSA exceeding 4 ng/mL, warrants urological referral before continuing therapy.

Suppression of Spermatogenesis and Male Fertility

Mechanism and Onset

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis by reducing pulsatile GnRH release, which in turn lowers LH and FSH. Without FSH, Sertoli cells cannot support normal sperm maturation. Spermatogenesis suppression is not immediate. Sperm counts typically begin to fall between weeks 6 and 12 of therapy, reaching a nadir (often azoospermia or severe oligospermia) by 3 to 6 months. [7]

This effect is frequently underestimated in younger men who present for TRT without disclosing a desire for children.

Duration of Suppression After Stopping

Recovery of spermatogenesis after stopping testosterone therapy is not guaranteed and is not fast. A systematic review published in the Journal of Urology found that 67% of men recovered baseline sperm counts by 12 months after stopping, and 90% recovered by 24 months, but 10% remained azoospermic at 2 years. [8] Men who used testosterone for longer periods had slower recovery.

What to Tell Patients Before Starting

Any male patient who may want to father children should be counseled explicitly before starting AndroGel. Alternatives such as clomiphene citrate or human chorionic gonadotropin (hCG) preserve the HPG axis and maintain spermatogenesis while raising testosterone levels. If a patient starts AndroGel and then wants to conceive, the stopping-to-conception timeline can span 12 to 24 months.

Cardiovascular Effects: A Signal That Took Years to Clarify

Background on the Controversy

Testosterone therapy and cardiovascular risk generated significant regulatory attention after a 2013 observational study in JAMA reported a higher rate of cardiovascular events in veterans who had coronary angiography and then received testosterone therapy. [9] The FDA subsequently required large cardiovascular outcomes trials. The most important of these was TRAVERSE.

TRAVERSE Trial Results

TRAVERSE (NCT03518034) enrolled 5,246 men aged 45 to 80 with hypogonadism (testosterone <300 ng/dL) and either established or high risk for cardiovascular disease. Participants received transdermal testosterone 1.62% gel or placebo for a mean follow-up of 33 months. The primary endpoint, major adverse cardiovascular events (MACE: non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death), occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (hazard ratio 0.96, 95% CI 0.78 to 1.17), establishing non-inferiority. [4]

However, TRAVERSE also found that atrial fibrillation was significantly more common in the testosterone group: 3.5% versus 2.4% (P<0.05). Acute kidney injury and pulmonary embolism were also numerically higher, though confidence intervals were wide for those endpoints. [4]

What This Means Clinically

The TRAVERSE data reassured clinicians that testosterone therapy in appropriately selected hypogonadal men does not increase overall MACE risk. The atrial fibrillation signal, though, is a delayed-onset concern. AF risk did not cluster at initiation; it accumulated over months of follow-up. Clinicians should ask about palpitations, dyspnea on exertion, or new fatigue starting 3 or more months into therapy, not just in the first weeks.

Lipid Profile Changes

HDL Suppression Over Time

Transdermal testosterone has a milder effect on lipids than oral alkylated androgens, but it is not neutral. HDL cholesterol tends to decline modestly with sustained testosterone use. A Cochrane review of testosterone therapy in men found a mean HDL reduction of approximately 0.49 mmol/L (roughly 19 mg/dL) across formulations, with transdermal preparations showing smaller reductions than oral forms. [10]

The HDL effect generally takes 3 to 6 months to stabilize. A single fasting lipid panel at 3 months captures the early shift; a panel at 12 months reflects the steady-state impact. Clinicians should not skip the 12-month lipid check, particularly in men who started therapy with borderline HDL levels.

LDL and Triglyceride Effects

LDL and triglyceride changes with transdermal testosterone are typically small and inconsistent across trials. If a patient's LDL rises significantly between the 3-month and 12-month checks, it is worth ruling out dietary change or statin non-adherence before attributing the change to testosterone alone.

Bone Density: A Positive Effect That Also Takes Time

Testosterone therapy improves bone mineral density in hypogonadal men, but this is a slow process. The T-Trial Bone Sub-trial (N=211) found that testosterone increased volumetric bone mineral density at the spine by 7.5% and trabecular bone score improved significantly over 12 months compared with placebo. [11] The benefit was not apparent at 3 months; it required a full year of therapy to emerge in DXA scanning.

This matters because some clinicians order a baseline DXA at initiation and then repeat it at 6 months. Six months is too early to detect a meaningful change. The Endocrine Society guideline recommends repeating DXA after 1 to 2 years of therapy in men who had low bone density at baseline. [5]

Sleep Apnea Worsening

A Delayed and Often Missed Effect

Testosterone can worsen or precipitate obstructive sleep apnea (OSA). The mechanism involves central chemoreceptor modulation and possible effects on upper airway muscle tone. This effect does not always appear in the first weeks. Some men who had mild, undiagnosed OSA before starting AndroGel develop clinical symptoms, including excessive daytime sleepiness, partner-reported snoring, or morning headaches, between months 1 and 3 of therapy.

The AndroGel prescribing information lists sleep apnea as a risk, particularly in men who are obese or have chronic lung disease. [1] If a patient reports new or worsening sleep symptoms after starting therapy, a sleep study (polysomnography) is warranted before continuing at the current dose.

Secondary Exposure: A Delayed Risk to Others

Transfer to Children and Female Partners

AndroGel gel remains transferable from the application site to other people for up to 2 hours after application if the area is not covered or washed. In children, even brief exposure can cause premature pubic hair development, clitoral or penile enlargement, and advanced bone age that permanently reduces adult height potential. The FDA required a black-box warning on all testosterone gel products after receiving post-marketing reports of virilization in children. [1]

The delayed component here is that the child's signs may not appear for weeks after the first transfer event, making the connection to AndroGel easy to miss. The FDA's FAERS database has documented multiple pediatric cases where the diagnosis was delayed by 2 to 6 months. [12]

Prevention Protocol

Patients should apply AndroGel to shoulders or upper arms, wash hands immediately after application, cover the application site with clothing before any skin-to-skin contact, and shower before expected close contact with children or pregnant partners. These steps eliminate nearly all transfer risk.

Mood and Cognitive Changes

Mood effects of testosterone therapy can go in either direction. Some men report improved energy and motivation within the first 3 weeks, a relatively early effect. The delayed picture is more complicated. Sustained supraphysiologic testosterone levels, which can occur if the dose is not adjusted after the 3-month lab check, may contribute to irritability, mood lability, or increased aggression over months of therapy.

A trial published in JAMA Internal Medicine found that men randomized to testosterone gel showed no significant improvement in vitality or overall quality of life at 12 months compared with placebo, though sexual function improved modestly. [13] This finding challenges the expectation that mood benefits simply accumulate over time.

The HealthRX clinical team uses a structured delayed-monitoring checklist for all patients starting AndroGel, with defined lab panels at baseline, 3 months, 6 months, and 12 months. Each check includes hematocrit, PSA, fasting lipids, LH, FSH, and total testosterone. Patients also complete a validated mood and symptom questionnaire (the ADAM questionnaire) at each visit to capture subjective changes that may not appear on labs.

Skin and Dermatological Effects Over Time

Acne Development

Acne from testosterone therapy is usually not immediate. In most men, it develops 4 to 12 weeks after starting therapy as sebaceous glands respond to rising androgen levels. The back, chest, and shoulders are common sites, coinciding partly with application areas. Mild acne often responds to topical benzoyl peroxide or retinoids; severe or cystic acne may require dose reduction.

Application-Site Skin Changes

Chronic application to the same anatomical site can cause gradual skin changes including folliculitis, hyperpigmentation, or mild atrophy over months of daily use. Rotating application sites within the approved areas (shoulders, upper arms) reduces this risk.

Lab Monitoring Timeline Summary

| Time Point | Labs to Order | |------------|--------------| | Baseline (before starting) | Total testosterone (AM), hematocrit, PSA, LH, FSH, fasting lipid panel, metabolic panel | | 3 months | Total testosterone, hematocrit, PSA, lipids | | 6 months | Hematocrit, PSA, symptom review | | 12 months | Full panel: testosterone, hematocrit, PSA, lipids, LH, FSH, metabolic panel, DXA if baseline was low | | Annually thereafter | Hematocrit, PSA, lipids, testosterone |

Rare But Documented Delayed-Onset Adverse Events

What Are the Rare Side Effects of AndroGel?

Rare delayed-onset adverse events reported in FDA FAERS data and published case literature include:

• Hepatic peliosis: Blood-filled cysts in the liver, more associated with oral androgens but reported with long-term transdermal use. [14]
• Deep vein thrombosis and pulmonary embolism: The FDA added a venous thromboembolism warning to all testosterone products in 2014 based on post-marketing reports. [1] Risk appears to concentrate in men with inherited thrombophilias who were not screened before starting.
• Gynaecomastia: Arises from peripheral aromatization of testosterone to estradiol. It typically develops after 3 to 6 months of therapy and is more common in men with higher baseline body fat.
• Testicular atrophy: LH suppression reduces intratesticular testosterone, leading to measurable testicular volume loss by 6 to 12 months. This is distinct from the cosmetic concern; it directly reflects gonadal suppression and correlates with spermatogenesis disruption.
• Worsening insulin resistance: Some long-term observational data suggest possible increases in fasting glucose in men with pre-existing metabolic syndrome after sustained testosterone therapy, though this effect is inconsistent across trials. [15]